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Neurohumoral Blood Pressure Regulation
in Lead Exposure
by Paolo Boscolo* and Marco Carmignanit
Previous human studies demonstrated that lead exposure may modify the metabolism of
catecholamines and of hormones controlled by the hypothalamo-pituitary axis and may affect the
kallikrein-kinin system. This paper reports unpublished data on the plasma renin activity of lead-
exposed workers; these results are in agreement with those of previous human and experimental
studies suggesting that the synthesis or release of renin is increased after short and moderate
exposure to inorganic lead and reduced whenever the exposure is prolonged.
Previous experimental investigations demonstrated that lead may act on the cardiovascular
system, with effects on the renin-angiotensin system, on the reactivity to stimulation of peripheral
catecholaminergic receptors, on sympathetic and vagal tone, and on reactivity to the stimulation of
baroreceptors. This paper reports the results of a study on male Sprague-Dawley rats that received
0, 15, 30, and 60 pg/mL of lead in drinking water for 18 months. Blood pressure was increased in
the rats receiving 30 and 60 ppm of lead; cardiac inotropism was augmented only in those receiving
the higher dose of the metal, and heart rate was not modified. Cardiovascular responses to agonists
indicated that lead exposure affects the renin-angiotensin system and induces sympathetic
hyperactivity by acting on central and peripheral sympathetic junctions increasing the
responsiveness to stimulation of a2-adrenoreceptors and by increasing the reactivity to stimulation of
cardiac and vascular P-adrenergic and dopaminergic receptors. The cAMP-dependent availability of
Ca2+ for contractile mechanisms ofthe cardiovascular muscle cells was affected by lead.
Human Studies
Several investigations on humans and experi-
mental animals have attempted to explain the effects of
lead exposure on several of the regulatory mechanisms
for blood pressure (BP). In patients heavily intoxicated
by lead (1), there were alterations of the hormones pro-
duced in the testis, adrenal cortex, and thyroid and al-
terations of those hormones regulated by the hypo-
thalamo-pituitary axis. Lead-exposed children (2), but
not hospitalized lead-exposed workers (3), had an in-
crease of urinary catecholamines and their metabo-
lites.
Urinary. kallikrein (an enzyme synthesized in the
kidney), which activates kinins (peptides with vaso-
dilatory and natriuretic action), was reduced i n
patients with essential hypertension. Urinary kalli-
krein activity was normal in young, healthy lead-
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exposed men and was low or absent in old, hyperten-
sive and/or nephropathic lead-exposed subjects (4,5). In
22 hospitalized lead-exposed workers, there was a weak
but statistically significant correlation between uri-
nary kallikrein activity and plasma renin activity
(PRA) (5).
The present study describes all the cases of lead-
exposed workers hospitalized at Catholic University of
Rome, in which PRA was determined with previously
described procedures (5). PRA was determined in 34
workers and in 21 control subjects both in the supine
position and after 1 hr of programmed activity in the
upright position. The workers were divided into four
groups, on the basis oftheir age and length of exposure
to inorganic or tetraethyl lead: group 1, 15 workers
younger than 38 years with exposure to inorganic
lead for less than 8 years; group 2, 4 workers older than
42 years with short exposure to inorganic lead; group
3, 8 workers older than 42 years and exposed for more
than 12 years to inorganic lead; group 4, 7 men em-
ployed for more than 8 years in a factory producing
tetraethyl lead.
In the subjects examined, 24-hr urine 6-amino-
levulinic acid and lead excretion rates, before and after
a 3-day versenate treatment, were determined; renalBOSCOLOAND CARMIGNANI
function was assessed by performing the 'I3I-hippuran
renogram and the creatinine clearance. Three of the 15
young lead-exposed men (group 1) presented arterial
hypertension and another 2 had slight renal impair-
ment; the mean PRA of this group, determined in the
erect position, was significantly elevated in relation to
that of control subjects of similar age (Table 1). The 4
workers in group 2 did not have modifications of PRA
(there was only one case of a slight renal impairment).
The patients in group 3 were suffering from arterial
hypertension, nephropathy, or myocardial
atherosclerosis. The PRA of this group manifested
blunted or suppressed responses to stimulation by
standing. Six ofthe 7 workers exposed to tetraethyl lead,
with low lead body burden (group 4), presented hy-
pertension or renal impairment, but PRA was reduced
in only one case.
The workers with hypertension and/or nephrop-
athy presented different levels of PRA in relation to the
length of exposure to lead: in the 5 young workers from
group 1, PRA was greatly augmented following the
change of position; in the older workers of group 3, the
response to the stimulation was reduced.
It seems likely that short lead exposure of healthy
young subjects may increase the synthesis and/or
release of renin from the juxtaglomerular cells; pro-
longed exposure may reduce the response of the
juxtaglomerular apparatus to stimulations. A recent
study of Campbell et al. (6) found increased PRA and
plasma aldosterone in men with occupational exposure
to lead for a relatively short period.
The results ofthe present study are also in agreement
with the experimental investigations of Victery et al.
(8-10), which demonstrated an increase in PRA in
rats after a short period of lead exposure and reduced
PRA whenever the exposure of the animals to the same
doses of lead was initiated in utero and continued for
several months.
Experimental Studies
In vivo and in vitro experimental studies have
demonstrated that lead exposure may modify the
mechanisms regulating the BP by acting not only on
the juxtaglomerular apparatus (8-10), but also on pe-
ripheral vascular receptors (11-13), on the sympathetic
nervous system (11-12), and on myocardial contrac-
tility (11-14).
In previous studies (11,12), our group examined the
cardiovascular function of male Sprague-Dawley rats
receiving 50 ,ug/mL of lead in drinking water for 160
to 180 days. Mean blood lead values of control and
exposed animals were 13 and 38 ,g/mL, respectively;
kidney values were 0.3 and 3.2 ,ug/g (dry weight); and
brain levels were 0.1 and 1.5 ,ug/g. Lead-exposed rats
showed, in comparison to controls, a mean increase of
systolic BP of 56 mm Hg and of diastolic BP of 41 mm
Hg. In these animals the maximum rate of rise of
blood pressure (dP/dt) was also significantly aug-
mented; heart rate (HR) did not differ from that of the
controls. In the exposed rats the responses to norepin-
ephrine [acting principally on a1 and a2-adrenore-
ceptors (15,16)] were augmented; responses to the lower
doses of epinephrine (which stimulates principally 1
and P2-adrenoreceptors, inducing hypotension and
increasing inotropism) were more evident. Responses
to the higher doses of epinephrine (acting on both a-
and J8-adrenoreceptors, increasing BP and dP/dt) were
unmodified in relation to the controls. In the exposed
rats the pressor responses to angiotensin II were
increased; responses to angiotensin I, which is trans-
formed to angiotensin II by angiotensin converting
enzyme, were unchanged, suggesting a possible in-
hibition of this enzyme. In the exposed animals,
bilateral carotid occlusion, which stimulates afferent
baroreflex pathways, induced lower effects on BP and
dP/dt than in the controls. In the lead-exposed rats,
hexamethonium (a blocker of the sympathetic post-
Table 1. Urinary lead and plasma renin activity in groups ofworkers with different age
and length ofexposure to inorganic or tetraethyl lead.a
Cases with Urine lead Vg/24 hr PRA ng/mIhr No. of Age, Exposure, hypertension U l
cases years years or nephropathy Before EDTA Max during EDTAb Supine Erect
Group 1: young workers with short exposure to inorganic lead
15 28±2 3±1 5 101±16 2092±333 2.10±0.43 6.36±0.98*
Group 2: old workers with short exposure to inorganic lead
4 46 ± 2 3 ± 1 1 57 14 1537 ± 302 0.70± 0.28 2.05 ± 0.42
Group 3: old workers with prolonged exposure to inorganic lead
8 53 ± 2 27 ± 3 7 134 ± 30 2805 ± 1513 (4) 0.87 ± 0.36 1.04 ± 0.3 7
Group 4: old workers with prolonged exposure to tetraethyl lead
7 48±4 18±3 6 29±5 657± 112 0.80±0.19 2.37±0.64
Young controls
11 27±2 <50 0.90 ± 0.23 3.32 ± 0.47
Old controls
10 52±2 <44 0.82 ± 0.34 2.52 ± 0.28
aAllvalues represent means ± SEM. Numbers in parentheses are numbers ofcases in which the determinations were made.
bl.5 g ofCaNa2-EDTA IVeach day for 3 days.
*Significantly different from control group, p < 0.05.
tSignificantly different from control group, p < 0.01.
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ganglionic fibers, which induces systemic hypo-
tension, bradycardia, and reduces dP/dt) presented
greater effects than in the control animals. On the
other hand, lead exposure reduced the effects of
vagotomy. On the whole, this first experiment
demonstrated that lead treatment in rats induces
baroreflex hyposensitivity, peripheral sympathetic
hyperactivity, hypersensitivity to the stimulation of
both a- and P-adrenoreceptors, and reduction of vagal
tone.
Recent Findings
The purpose of the present study was to further
investigate the effects of chronic lead exposure in rats
on the renin-angiotensin system, on the cardiovas-
cular reactivity to catecholaminergic agonists, on
some neurosynaptic events at the sympathetic junc-
tion, as well as on the availability of Ca2+ and cAMP in
the cardiovascular muscle cell for contractile mecha-
nisms.
Materials and Methods
Forty weanling male Sprague-Dawley rats, ran-
domly divided in four equal groups and fed a
standard laboratory diet, received in deionized drink-
ing water 0, 15, 30, and 60 ,ug/mL oflead (as acetate) for
18 months. At the end of lead exposure, the rats were
anesthetized with sodium thiopental (50 mg/kg IP).
The trachea was cannulated to allow spontaneous
breathing. The body temperature of the animals was
kept constant at 370C by an electrically heated table. For
assessing cardiohemodynamic parameters, poly-
ethylene catheters were placed in the left femoral artery
for recording BP and in the right femoral vein for
drug administration. Systolic and diastolic BP were
measured by means of a P23Db Statham pressure
transducer and averaged electronically. A Biotronex
derivative computer was used for determining (by
differentiating the pulsatile aortic BP) the dP/dt as
index of cardiac inotropism. Heart rate was measured
by a Beckman cardiotachometer coupler, which was
triggered by the R-peak of the lead II electrocar-
diogram. The cardiovascular parameters were contin-
uously monitored on a Beckman-type RM dynograph
recorder.
Pressor, inotropic, and chronotropic responses were
determined following IV injection of the following
substances: phenylephrine (10 ,ug/kg, Sigma);
isoprenaline (0.625 jg/kg, Merck); dopamine (12.5
jig/kg, Merck); IV infusion of clonidine (25 ,ug/kg,
Boehringer Ingelheim); cocaine (2.5 mg/kg,
Angelini); angiotensin I and II (0.50 jig/kg, Sigma)
before and 30 min after IP administration of captopril
(5 mg/kg; Squibb); papaverine (2 mg/kg, Merck);
verapamil (125 jg/kg, Knoll AG); and dibutyryl
adenosine 3'-5'-monophosphate (dBcAMP, 5 mg/kg;
Fluka AG). All drugs were dissolved in 0.9% saline
solution and were injected in a volume of 25 jiL over a
period of 5 sec (with the exception of clonidine
administered by IV infusion over a 2-min period and
captopril administered IP). The catheter was flushed
with 50 ,uL of 0.9% saline solution. All doses of the
administered substances were expressed in terms of
freebasesand peakresponseswere considered.
Blood samples were collected for the determination of
lead. The animals were killed by exsanguination and
organs were excised for determining the lead content
(referred to as the wet weight) and for histological
examination. Lead content of blood and organs was
determined by atomic absorption spectrophotometry
(16).
The statistical comparison of the data was made by
Dunnett's t-test for multiple comparison.
Results
Throughout the exposure period, body weight and
general appearance of the animals were not modified
by the lead exposure. Lead was increased in blood,
kidney, and brain of the treated rats at levels related to
the administered dose ofthe metal (Table 2).
The rats receiving 15 ppm of lead did not demon-
strate any modification of the basal cardiovascular pa-
rameters (Fig. 1). Diastolic BP was significantly aug-
mented in the rats receiving 30 ppm of lead; the
animals treated with 60 ppm oflead presented increases
ofboth systolic and diastolic BP, ofthe dP/dt, but not of
the heart rate.
In the rats receiving 15 ppm lead, only the pressor
responses to angiotensin I and to dibutyryl-cAMP were
modified (Table 3). All the exposed rats showed similar,
reduced BP responses to angiotensin I, but not to
angiotensin II. Captopril, an inhibitor of the angio-
tensin I converting enzyme, produced similar de-
creases in both control and exposed animals (about 20
mm Hg); however, captopril did not modify the
responses to angiotensin I and II in the rats receiving
15 ppm of lead, although it reduced the pressor
responses to the same agonists in the animals treated
with the higher doses of lead. In all the exposed rats,
dibutyryl-cAMP, which enters cardiac and vascular
muscle cells, induced a hypotensive response. Dibu-
tyryl-cAMP provoked an increase of BP in the controls.
In the rats exposed to 30 and 60 ppm of lead, the
hypotensive responses to isoprenaline, a Pl12-adreno-
ceptor agonist, were potentiated, and the moderate
hypertensive responses to dopamine were reversed. In
Table 2. Lead in blood, kidney and brain of rats receiving
different doses oflead in drinking water for 18 months.a
Dose, Blood, Kidney Brain,
Group pg/mL pg/dL pg/gb pg/gb
Control 0 3.9 + 0.2 0.08 + 0.02 < 0.03
Exposed 15 7.4 ± 0.5* 0.4 +0.1 < 0.07
Exposed 30 11.5 + 0.9* 1.0 O O1 < 0.08
Exposed 60 16.7 + 0.6* 2.7 ± 0.6* 0.8 ± Of
aThe values represent means + SEM.
bLead contents ofkidney and brain are related to the wetweight.
*Significantly different from control group,p < 0.05.
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FIGURE 1. Systolic and diastolic blood pressure, heart rate, and maximum rate of rise of the left ventricular pressure (dP/dt) in rats receiving 0, 15,
30, and 60 ppm oflead in drinking water for 18 months.
Table 3. Peak changes in mean blood pressure following IV administration ofvarious substances in
rats receiving different doses oflead in drinkdng water for 18 months.
Changes in mean blood pressure, mm Hg
Exposure, pg/mLoflead
Substance administered Control 15 30 60
Phenylephrine, 10pg/kg + 39 ± 2 + 40± 2 +36 ± 5 + 35± 2
Isoprenaline, 0652 pg/kg -22± 3 -28± 3 - 34± 3* -41 4*
Dopamine, 12.5pg/kg + 13±2 + 12±2 -2±1* -13±2*
Tyramine,450Opg/kg +46±4 +38±3 +36±4 +27±6*
Clonidine, 25 pg/kg -11 ± 3 - 13± 5 - 17± 5 -25 ± 1
Cocaine, 2.5 pg/kg + 19±3 + 22±3 + 18 ± 4 + 16± 2
Angiotensin I, 0.5 pg/kg
Before captoprila + 42 ± 2 + 26± 2* + 24± 3* +32± 2*
Aftercaptopril +43 ± 3 + 24 ± 3 + 15± 3* + 10± 3*
Angiotensin II, 0.5 pg/kg
Before captopril + 47± 7 + 49 ± 7 + 50± 4 + 42 ± 3
Aftercaptopril + 52 ± 4 + 51 ± 8 + 44 ± 5 + 29± 5*
Papaverine, 2 mg/kg - 19± 3 17 ± 2 - 18± 2 - 23± 3
Vrapamil, 125 pg/kg - 27± 5 - 29 2 - 31± 3 -26± 5
Dibutyryl cAMP, 5 mg/kg + 56 ± 5 - 12 3' - 15 4' - 13 4'
aCaptopril (5 mg/kg) was administered by IP route. It decreased blood pressure similarly in control and lead-exposed groups ( 20 mm Hg).
*Significantly different from control group,p < 0.05.
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the rats receiving 60 ppm lead, the hypertensive effects
induced by tyramine (releasing the labile pool of
norepinephrine from the axonal postganglionic adre-
nergic terminals) were reduced; the hypotensive effects
of clonidine (which reduces the sympathetic tone,
principally by stimulating X2-adrenoreceptors of cen-
tral sympathetic junctions) were potentiated. On the
other hand, the cardiovascular responses to each of the
following pharmacologic agents were not modified by
lead exposure: phenylephrine (a specific xl-adreno-
receptor agonist); papaverine (a smooth muscle relax-
ant that inhibits the phosphodiesterase); cocaine (a
blocker of the neuronal uptake of noradrenaline); and
verapamil (a calcium antagonist that inhibits both in
myocardial and vascular muscle cells the slow influx
of calcium through receptor operated channels). In the
exposed rats, heart rate was not modified by these
substances. Histological examination by light micro-
scopy did not reveal alterations in the organs of the
exposed rats.
Discussion
This study confims that long-term exposure of rats
to lead is able to increase both blood pressure and
cardiac inotropism without morphological modifica-
tions, as observed by light microscopy.
The reduced responses to angiotensin I, but not to
angiotensin II, in the lead-exposed rats may be
explained by a possible inhibition of the converting
enzyme and/or by an increase in plasma renin
activity augmenting the level of angiotensin I in the
plasma. The reduced responses to angiotensin I and II
after captopril in the rats receiving higher doses of lead
may be related to an effect of the metal on the
mechanisms involved in the homeostatic regulation
of the renin-angiotensin system.
The increased hypotensive response to clonidine,
resulting from stimulation of the a2-adrenoreceptors
(13), also with inhibition of the release of norepin-
ephrine from the central sympathetic axonal endings,
indicates that the increase of the sympathetic tone,
demonstrated in the first experiment by the aug-
mented responses to the ganglioplegic hexameth-
onium (11,12), was centrally mediated. Moreover, the
reduction observed in the treated animals of the tyra-
mine-sensitive pool of norepinephrine in the sym-
pathetic endings may be related to increased activity of
the postganglionic fibers.
In the lead-exposed rats the unchanged cardiovas-
cular effects following phenylephrine or cocaine prove
that lead neither significantly affects the reactivity to
the stimulation of al-adrenoreceptors nor the neu-
ronal uptake of noradrenaline.
The cardiovascular responses induced by the
activation of ,B-adrenoreceptors by isoprenaline and of
dopaminergic receptors by dopamine were augmented
in lead-exposed rats. It is important to point out that
a2-, I3l-, and P2-adrenoreceptors, as well as the dopamin-
ergic receptors, act together to regulate the cyclic
nucleotide-dependent availability of calcium for con-
tractile systems (15,16). Dibutyryl cAMP, which enters
cardiovascular muscle cells, induced reverse effects in
the lead-exposed rats. This may be due to a depletion of
cAMP produced from ATP due to impairment of the
high energy phosphate pathway (14). On the other
hand, it must be pointed out that the altered cAMP-
dependent availability of Ca2+ for contractile mecha-
nisms in cardiovascular muscle cells was related
neither to the phosphodiesterase activity nor to the
verapamil-sensitive Ca2+ channels.
This study confirms that chronic lead exposure
affects the cardiovascular system, not only by in-
ducing metabolic changes (as those related to the me-
tabolism of calcium or of the high energy phosphate
pathway) (7,14,16) which are able to produce neuro-
humoral disorders, but also by inducing neurogenic
and humoral effects that may involve the regulation of
metabolic processes.
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